These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20606044)

  • 21. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
    Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E
    Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
    Pratesi G; Petrangolini G; Tortoreto M; Addis A; Belluco S; Rossini A; Selleri S; Rumio C; Menard S; Balsari A
    Cancer Res; 2005 Jul; 65(14):6388-93. PubMed ID: 16024642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
    Feldmann G; Dhara S; Fendrich V; Bedja D; Beaty R; Mullendore M; Karikari C; Alvarez H; Iacobuzio-Donahue C; Jimeno A; Gabrielson KL; Matsui W; Maitra A
    Cancer Res; 2007 Mar; 67(5):2187-96. PubMed ID: 17332349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
    Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM
    Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
    Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
    Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
    Bharthuar A; Pearce L; Litwin A; LeVea C; Kuvshinoff B; Iyer R
    JOP; 2009 Sep; 10(5):523-7. PubMed ID: 19734629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
    BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
    Rovida A; Castiglioni V; Decio A; Scarlato V; Scanziani E; Giavazzi R; Cesca M
    Mol Cancer Ther; 2013 Oct; 12(10):2237-47. PubMed ID: 23918831
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
    Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
    Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
    Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
    Bisht S; Mizuma M; Feldmann G; Ottenhof NA; Hong SM; Pramanik D; Chenna V; Karikari C; Sharma R; Goggins MG; Rudek MA; Ravi R; Maitra A; Maitra A
    Mol Cancer Ther; 2010 Aug; 9(8):2255-64. PubMed ID: 20647339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
    Katz MH; Takimoto S; Spivack D; Moossa AR; Hoffman RM; Bouvet M
    J Surg Res; 2003 Jul; 113(1):151-60. PubMed ID: 12943825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.